HEPISLAV-B

What Happened Dynavax Technologies Corporation (NASDAQ: DVAX) traded up 3.7 percent Wednesday after management announced the Centers for Disease Control and Prevention will recommend HEPLISAV-B as an adult vaccination for hepatitis B. The official nod from the Advisory Committee on Immunization...